These studies have reported a prevalence of PDL1 amplifications in immune-hot tumours [12, 13] as opposed to a high occurrence of APC, KRAS, IDH1 or FGFR3 mutations in immune-cold tumours [12–15]. The gene discussed is KRAS; the disease is neoplasm.